Monkeypox virus-neutralising antibodies detected against Clade Ib and Clade IIb in healthy individuals following MVA-BN vaccination
Sheridan, V. H.; Duffy, C. W.; Dunning, J.; Turtle, L.; Hiscox, J. A.; Subramaniam, K. S.; ISARIC4C Investigators,
Show abstract
Recently, a novel subclade of mpox virus (MPXV), clade Ib, has emerged in Eastern Democratic Republic of the Congo (DRC). Modified vaccinia Ankara--Bavarian Nordic (MVA-BN) is a third-generation smallpox vaccine that is authorised and in use as a vaccine against mpox. MVA-BN provides approximately 78% protection against disease to Clade IIb MPXV, but there are no data for Clade Ib. We used a plaque reduction neutralisation assay (PRNT) with MPXV clinical isolates from Clade Ib and IIb to investigate immunity in vaccinated health care workers. Here we show that a two-dose regimen of MVA-BN can induce MPXV-neutralising antibodies against both clades, with higher responses to Clade IIb than Clade Ib. KEY POINTSO_LIVaccination with MVA-BN generates antibodies that can neutralise MPXV Clade Ib and IIb. C_LIO_LIDespite the small sample size paired analysis across the vaccine recipients demonstrate higher neutralisation to Clade IIb than Ib. C_LI
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV 93%
- Neutralization heterogeneity of United Kingdom and South-African SARS CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers 93%
- Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination 92%
Similar papers in this journal
- Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity 94%
- Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patients 93%
- Comparative performance of SARS CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity detection of infectious virus in clinical specimens 91%
Similar papers in this journal
- High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge: a case for continued use of masks post-vaccination 95%
- Antibody response after a single dose of BBV152 vaccine negatively correlates with pre-existing antibodies and induces a significant but low levels of neutralizing antibodies to Omicron variant 95%
- Prior vaccination with the rVSV-ZEBOV vaccine does not interfere with but improves the efficacy of postexposure antibody treatment in nonhuman primates exposed to Ebola virus 94%
Similar papers in this journal
- Immunogenicity, safety and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs 94%
- Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus vaccine following vaccination campaigns 94%
- Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.